azd-5423 azd-5423 azd-5423 is a nonsteroidal glucocorticoid and phase ii experimental drug being developed by astrazeneca and disclosed at the spring 2013 american chemical society meeting in new orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease. azd-5423identifiers iupac name 2,2,2-trifluoro-n-oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide cas number1034148-04-3 ypubchem cid24825740chemspider28536140unii641h0q518wcomptox dashboard (epa)dtxsid40145823 echa infocard100.205.965 chemical and physical dataformulac25h21f4n3o3molar mass487.455 g·mol−13d model (jsmol)interactive image smiles c((c1cccc(c1)oc)oc2ccc3c(c2)cnn3c4ccc(cc4)f)nc(=o)c(f)(f)f inchi inchi=1s/c25h21f4n3o3/c1-15(31-24(33)25(27,28)29)23(16-4-3-5-20(12-16)34-2)35-21-10-11-22-17(13-21)14-30-32(22)19-8-6-18(26)7-9-19/h3-15,23h,1-2h3,(h,31,33)/t15-,23-/m0/s1key:fcnqmdsjhaddft-wnskoxeysa-n it has completed a phase ii clinical trial.